NASDAQ:MGNX MacroGenics (MGNX) Stock Price, News & Analysis $2.05 -0.12 (-5.53%) Closing price 11/17/2026 04:00 PM EasternExtended Trading$2.05 0.00 (0.00%) As of 11/17/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About MacroGenics Stock (NASDAQ:MGNX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MacroGenics alerts:Sign Up Key Stats Today's Range$2.02▼$2.1850-Day Range$2.05▼$4.2052-Week Range$1.32▼$5.08Volume572,902 shsAverage Volume1.10 million shsMarket Capitalization$131.02 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingHold Company Overview MacroGenics, Inc. is a biotechnology company focused on discovering and developing antibody-based medicines, primarily for cancer. Founded in 2000 and headquartered in Rockville, Maryland, the company works on its own drug candidates and collaborates with other pharmaceutical and biotechnology companies. Its research uses antibody-engineering technologies, including platforms designed to engage immune cells against tumors and to deliver therapeutic payloads to cancer cells. MacroGenics’ portfolio has included margetuximab, marketed as Margenza, an antibody treatment approved in the United States for certain patients with HER2-positive metastatic breast cancer. The company’s development programs and collaborations span multiple regions, with partners involved in advancing or commercializing therapies in international markets. MacroGenics continues to focus on developing antibody-based treatments for cancer.AI Generated. May Contain Errors. Read More MacroGenics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreMGNX MarketRank™: 2.5459877366 of 5 starsMacroGenics scored higher than 51% of companies evaluated by MarketBeat, and ranked 516th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingMacroGenics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialMacroGenics has a consensus price target of $8.50, representing about 314.6% upside from its current price of $2.05.Amount of Analyst CoverageMacroGenics has only been the subject of 2 research reports in the past 90 days.Read more about MacroGenics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MacroGenics are expected to decrease in the coming year, from ($1.64) to ($1.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MacroGenics is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MacroGenics is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMacroGenics has a P/B Ratio of 5.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.99% of the float of MacroGenics has been sold short.Short Interest Ratio / Days to CoverMacroGenics has a short interest ratio ("days to cover") of 3.86, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MacroGenics has recently decreased by 2.19%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMacroGenics does not currently pay a dividend.Dividend GrowthMacroGenics does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.03 News SentimentMacroGenics has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for MacroGenics this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added MacroGenics to their MarketBeat watchlist in the last 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, MacroGenics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $129,086.00 in company stock.Percentage Held by Insiders13.60% of the stock of MacroGenics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.89% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MacroGenics' insider trading history. Receive MGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MGNX Stock News HeadlinesMacroGenics (NASDAQ:MGNX) Cut to Sell at Wall Street ZenNovember 17 at 3:42 AM | americanbankingnews.comMacroGenics, Inc. (NASDAQ:MGNX) Stock Now Rated "Hold" by Sell-Side BrokeragesNovember 16 at 2:01 AM | americanbankingnews.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out. | Weiss Ratings (Ad)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Thermo Fisher (TMO), MacroGenics (MGNX) and Diaceutics (OtherDIUXF)November 14, 2026 | theglobeandmail.comMacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate ProgressNovember 12, 2026 | markets.businessinsider.comMacroGenics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 12, 2026 | marketscreener.comMMacroGenics Q3 2026: What the Revenue Miss Actually SignalsNovember 12, 2026 | 247wallst.comMacroGenics (MGNX) Set to Announce Quarterly Earnings on WednesdayNovember 10, 2026 | americanbankingnews.comSee More Headlines MGNX Stock Analysis - Frequently Asked Questions How have MGNX shares performed this year? MacroGenics' stock was trading at $1.61 at the beginning of the year. Since then, MGNX shares have increased by 27.3% and is now trading at $2.05. How were MacroGenics' earnings last quarter? MacroGenics, Inc. (NASDAQ:MGNX) released its earnings results on Thursday, August, 13th. The biopharmaceutical company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.39. The biopharmaceutical company earned $32.83 million during the quarter, compared to analysts' expectations of $59.14 million. MacroGenics had a negative trailing twelve-month return on equity of 246.62% and a negative net margin of 45.37%. When did MacroGenics IPO? MacroGenics (MGNX) raised $75 million in an initial public offering on Thursday, October 10th 2013. The company issued 5,000,000 shares at $14.00-$16.00 per share. Who are MacroGenics' major shareholders? MacroGenics' top institutional shareholders include Marshall Wace LLP (2.11%), State Street Corp (1.83%), Pinnacle Associates Ltd. (1.02%) and Goldman Sachs Group Inc. (0.74%). Insiders that own company stock include William K Heiden, Ezio Bonvini and Jeffrey Stuart Peters. View institutional ownership trends. How do I buy shares of MacroGenics? Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MacroGenics own? Based on aggregate information from My MarketBeat watchlists, some other companies that MacroGenics investors own include Advanced Micro Devices (AMD), Micron Technology (MU), Tesla (TSLA), Bristol Myers Squibb (BMY), Alibaba Group (BABA), NVIDIA (NVDA) and TG Therapeutics (TGTX). Company Calendar Last Earnings8/13/2026Today11/18/20269th Annual Evercore ISI HealthCONx Conference11/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 3 weeks, MGNX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MGNX CIK1125345 Webwww.macrogenics.com Phone(301) 251-5172Fax301-251-5321Employees293Year Founded2000Price Target and Rating Average Price Target for MacroGenics$8.50 High Price Target$11.00 Low Price Target$6.00 Potential Upside/Downside+314.6%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.62 million Net Margins-45.37% Pretax Margin-112.87% Return on Equity-246.62% Return on Assets-31.36% Debt Debt-to-Equity RatioN/A Current Ratio2.75 Quick Ratio2.75 Sales & Book Value Annual Sales$149.50 million Price / Sales0.88 Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book5.26Miscellaneous Outstanding Shares63,910,000Free Float55,037,000Market Cap$131.02 million OptionableOptionable Beta1.33 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:MGNX) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredAmerica's Biggest Bank… Down?About 4,800 Chase customers reported problems in just 15 minutes on Monday. Many couldn't log in or move money...Decentralized Masters | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.